regulatory updates for mRNA therapeutics globally. Track guidance releases, approval decisions, and policy shifts across major health authorities. Provide a real time snapshot of the evolving landscape.
Global mRNA therapeutics regulatory sources, 2026 snapshot
Curated official and specialist sources covering 2026 guidance, policy proposals, approval decisions, clinical-trial activity, and vaccine-update recommendations across major authorities. The available results provide no directly supported 2026 mRNA-specific PMDA update, and no MHRA search result was found in one authority-specific search; the MHRA sources below provide the available official record.
EMA: approval decisions and vaccine-update policy
Official European Medicines Agency sources covering an mRNA product recommendation, antigen-composition recommendations for the 2026-2027 campaign, and the relevant variation pathway.
MHRA: mRNA-specific consultation and approval
Official UK sources covering draft guidance for individualised mRNA cancer immunotherapies and the approval of an mRNA COVID-19 vaccine.
TGA: mRNA policy, variant updates, and safety evidence
Official Australian sources covering the TGA's mRNA technology position statement, fast-tracking guidance for modified COVID-19 vaccines, product information, and laboratory testing.
Messenger RNA (mRNA) technology position statement | Therapeutic Goods Administration (TGA)
Health Canada: policy proposals and trial authorization
Sources covering Canada's proposed reliance and rolling-review reforms, regulatory-navigation proposals, drug announcements, and the available official announcements channel for product and trial decisions.
WHO: global vaccine policy and prequalification process
Official WHO sources covering 2026 COVID-19 vaccine antigen policy, the position paper, and a public consultation on the vaccine prequalification procedure. These sources are vaccine-focused rather than mRNA-therapeutic-specific.
FDA: official guidance and approval trackers
Official FDA landing pages for recently issued biologics guidance, newly added drug guidance, and 2026 novel drug approval decisions. The available search results do not establish a specific 2026 mRNA approval or mRNA-specific guidance item.
Cross-authority regulatory monitoring
Specialist regulatory coverage useful for tracking developments beyond the authority pages, including mRNA therapeutic progress, nucleic-acid regulation, and 2026 regulatory roundups. These sources should be checked against primary authority records before relying on a decision.
Crea el teu compte per conservar aquesta resposta i continuar-hi més tard.
Veiem alternatives:
- Modifica la consulta.
- Inicia un nou fil.
- Elimina les fonts (si s'han afegit manualment).
